FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: DARA

Sort
E.g., 2013-05-18
E.g., 2013-05-18
Enter a comma separated list of user names.

Stock-PR Reporting

FREE Daily Stock Alerts From Stock-PR.com

Tags:

DARA BioSciences, Inc. (Nasdaq:DARA) is a clinical stage pharmaceutical development company that acquires high quality, promising therapeutic molecules in early stage development (late pre-clinical or Phase 1). Acquired molecules have the potential to fill significant medical needs and represent large commercial opportunities for participation in large and growing markets.

SLXP, Salix Pharmaceuticals, Ltd.

** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.

SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.

DARA BioSciences, Inc (Nasdaq:DARA) announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

Global Hunter (GBLHF.PK)

Molybdenum has exceptional corrosion resistance to molten glass, numerous molten metals and aggressive exhaust gases as well as to numerous acids and other chemical substances. The corrosion resistance of molybdenum can be increased further by alloying, for example with tungsten.

Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

Tags:

DARA BioSciences, Inc. (Nasdaq:DARA) announced that an abstract has been accepted for presentation at the annual American Diabetes Association ("ADA") Scientific Sessions to be held in San Diego, CA, June 24 - 28, 2011. The presentation will provide details on the company's lead once-a-day, oral diabetes drug candidate DB959.

Tags:

DARA BioSciences, Inc. (DARA)

Diabetes mellitus is a condition where the body cannot maintain normal blood glucose levels.There are two types of Diabetes, Type 1 diabetes is an auto-immune disease where the body's immune system destroys the insulin-producing beta cells in the pancreas.

Tags:

Pages

ADVERTISE WITH US